Back to search results

MRC Postdoctoral Research Scientist in Senescence in Cancer and Ageing

MRC London Institute of Medical Sciences

Location: London
Salary: £32,302 to £35,143 * plus London allowances (£3,727 & £1,402) per annum
Hours: Full Time
Contract Type: Fixed-Term/Contract
Placed On: 14th May 2021
Closes: 14th June 2021
Job Ref: LMS - 1576

Novel models to study senescence and the SASP in cancer and aging

We have contributed to understand the role of senescence as a tumour suppressor mechanism (Collado et al. Nature 2005), in limiting iPSC reprogramming (Banito et al. Genes Dev 2009) or activating immune surveillance (Kang et al. Nature 2011). We have also contributed to identify molecular mechanisms controlling senescence (Gil et al. Nat Cell Biol 2004; Tordella et al. Genes Dev 2016) or the inflammatory phenotype associated with senescence (Acosta et al. Cell 2008; Acosta et al. Nat Cell Biol 2013; Herranz et al. Nat Cell Biol 2015; Georgilis et al. Cancer Cell 2018). We are also interested in identifying strategies to kill senescent cells to treat multiple diseases including cancer (Guerrero et al. Nat Metabolism 2019; Guerrero et al. Aging Cell 2020).

You will work on the identification and characterization of mechanisms regulating senescence and the senescence-associated secretory phenotype (SASP) in cancer and age-related diseases. The project will benefit of novel mouse models developed in our lab and yet unpublished insights on SASP regulation and senolytic sensitivities obtained from large scale screens carried out by us.

A strong background in molecular and cellular biology is required. Experience working with primary cells, familiarity with retroviral and lentiviral systems, with genetic or drug screens or with high content microscopy systems (such as InCell 2500) would be highly valued. You should have a Ph.D. degree in life sciences (or equivalent) and at least one first-author publication published or in press. A Home Office Personal License and experience with animal work is desirable but not essential.

In return, we offer a highly attractive benefits package including 30 days annual leave plus bank holidays and privilege days, competitive salary and generous pension scheme along with an interest free season ticket loan.

The LMS is directly funded by the Medical Research Council (part of UK Research and Innovation) and associated with Imperial College. The LMS provide excellent core facilities and support structures, including automated microscopy systems, next generation sequence and proteomics. The Cell Proliferation Group is part of the Epigenetics Section and interacts with other groups in the LMS studying cell cycle, cancer, and chromatin organisation

UK Research and Innovation is an entity that brings together nine partners to create an independent organisation with a strong voice for research and innovation, more information can be found at

For informal enquiries, please contact Jesús Gil via email (

The post will be available from late summer.

For full details of this post and to complete an online application, please click 'Apply' and upload your CV, names and contacts of two scientific references along with a covering letter stating why you are applying for this role (providing evidence against the requirements of the job as per the job description and person specification).

Closing date: 14 June 2021

* Additional allowances comprise of a £1,000 lump sum Settlement Allowance plus a yearly Training Allowance of £850 in the 1st year, paid in monthly instalments. The Training Allowance increases to £1,300 in year two, and £1,800 in the third year.

We value your feedback on the quality of our adverts. If you have a comment to make about the overall quality of this advert, or its categorisation then please send us your feedback
Advert information

Type / Role:

Subject Area(s):


Job tools
More jobs from MRC London Institute of Medical Sciences

Show all jobs for this employer …

More jobs like this
Join in and follow us

Browser Upgrade Recommended has been optimised for the latest browsers.

For the best user experience, we recommend viewing on one of the following:

Google Chrome Firefox Microsoft Edge